Skip to main content

Ardelyx, Inc.

corporate_fare Company Profile

Ardelyx, Inc.

ARDX·NASDAQ·Life Sciences·CIK 0001437402

Ardelyx is a commercial-stage biopharmaceutical company focused on developing and selling innovative medicines for significant unmet medical needs. The company currently markets two therapies derived from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor discovered and developed by Ardelyx. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. One therapy, branded as IBSRELA®, is approved in the U.S. for treating adults with irritable bowel syndrome with constipation (IBS-C). Ardelyx is also evaluating tenapanor in a Phase 3 clinical trial for adult patients with chronic idiopathic constipation (CIC) to expand the eligible patient population. The second therapy, branded as XPHOZAH®, is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis. It is used as an add-on therapy for patients who do not respond adequately to phosphate binders or cannot tolerate any dose of phosphate binder therapy. In addition to commercializing IBSRELA and XPHOZAH, Ardelyx is developing a next-generation NHE3 inhibitor.

Ardelyx, Inc. (NASDAQ:ARDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for ARDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ARDX spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Ardelyx 10-Q: Q3 Revenue $127.7M, Net Loss $0.7M, $285.3M Cash, New Securities Suit Disclosed
  • Ardelyx Q3 Product Revenue $125.5M, Net Loss Narrows to $0.7M; Guidance Reiterated
  • Ardelyx Posts $127.7M in Q3 Revenue, Topping Last Quarter's Record
  • Ardelyx Chief Commercial Officer Resigns Effective August 28
  • Ardelyx Slashes IBSRELA Guidance by $60M Despite Record Q2 Revenue

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$407.32M
Net Income
-$61.6M
Diluted EPS
-$0.26
Op. Cash Flow
-$42.48M
Free Cash Flow
-$43.98M
Gross Profit
$367.78M
Operating Income
-$40.98M
Cash & Equivalents
$68M
Total Debt
$202.83M
Debt / Equity
1.21×
Net Margin
-15.1%
Shares Outstanding
244.35M sh
Source: 10-K · filed 2026-02-19 · accession 0001437402-26-000013

Short Interest & Short Volume

7.53 days to cover

FINRA reported short interest of 29,205,209 shares in ARDX as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 46.1% of ARDX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)29,205,209 shares as of October 30, 2026
Change vs prior period▼ 3.4%
Days to cover7.53 at avg daily volume of 3,877,282
Daily short volume (FINRA facilities)46.1% of 2,310,349 shares on November 20, 2026
5-day average short volume48.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ARDX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-17.

Equity Plan Share Increase Approved · Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$2.99
52-week range · as of 2026-11-03 $2.96 – $8.4
Market cap
$751.6M
Volume
6.2M (1.3× avg)
3-mo avg 4.8M
Live data · 2026-11-21 17:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARDX - Latest Insights

ARDX
Nov 03, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.08
Real-time Price: $2.99 info
Change: -$0.090 (-3%) info
Market Cap: $751.604M info
ARDX
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.04
Real-time Price: $2.99 info
Change: -$0.0508 (-2%) info
Market Cap: $751.604M info
ARDX
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.05
Real-time Price: $2.99 info
Change: -$0.060 (-2%) info
Market Cap: $751.604M info
ARDX
Aug 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.99 info
Change: -$1.05 (-26%) info
Market Cap: $751.604M info
ARDX
Aug 06, 2026, 4:49 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.08
Real-time Price: $2.99 info
Change: -$1.09 (-27%) info
Market Cap: $751.604M info
ARDX
Aug 06, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.50
Real-time Price: $2.99 info
Change: -$1.51 (-34%) info
Market Cap: $751.604M info
ARDX
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $2.99 info
Change: -$1.11 (-27%) info
Market Cap: $751.604M info
ARDX
Jul 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.31
Real-time Price: $2.99 info
Change: -$2.32 (-44%) info
Market Cap: $751.604M info
ARDX
Jun 17, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.84
Real-time Price: $2.99 info
Change: -$2.85 (-49%) info
Market Cap: $751.604M info
ARDX
Apr 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.13
Real-time Price: $2.99 info
Change: -$3.14 (-51%) info
Market Cap: $751.604M info
ARDX
Feb 19, 2026, 4:05 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $6.25
Real-time Price: $2.99 info
Change: -$3.26 (-52%) info
Market Cap: $751.604M info
ARDX
Feb 19, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.38
Real-time Price: $2.99 info
Change: -$3.39 (-53%) info
Market Cap: $751.604M info
ARDX
Jan 08, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.16
Real-time Price: $2.99 info
Change: -$3.17 (-51%) info
Market Cap: $751.604M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets